{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:57Z","timestamp":1791839877563,"version":"4.3.4"},"reference-count":100,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Pityriasis rubra pilaris (PRP) is a rare, papulosquamous, inflammatory skin disease. PRP represents a therapeutic challenge. The rarity of this disease and its possible spontaneous remission makes the conduction and interpretation of therapeutic studies particularly difficult. Moreover, PRP not infrequently proves resistant to common topical and conventional systemic therapies. In this context, numerous biologic agents have been reported in PRP treatment. The aim of our manuscript was to review the current literature to evaluate the possible role of biologics targeting the IL17\/23 axis in PRP management. Recent cases in the literature have highlighted the use of several promising drugs: IL-17 inhibitors, IL-23 inhibitors, and the IL-12\/23p40 inhibitor ustekinumab. However, it should be noted that all these drugs are approved for moderate-to-severe plaque psoriasis and their use in PRP is off label. The treatment of PRP is based on clinical experience, case reports or case series reported in the literature, as randomized controlled trials are difficult to conduct due to the rarity of the condition. Despite data on the efficacy of drugs targeting IL-17 and IL-23 being promising, they are still limited. Certainly, further studies are desirable to better characterize PRP and establish shared guidelines.<\/jats:p>","DOI":"10.3390\/life14080923","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T15:47:32Z","timestamp":1721836052000},"page":"923","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"first","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Portarapillo","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Esposito","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4262-5547","authenticated-orcid":false,"given":"Antonia","family":"Salsano","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Guerriero","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40257-017-0338-1","article-title":"A Review on Pityriasis Rubra Pilaris","volume":"19","author":"Wang","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-4362.1999.00513.x","article-title":"Pityriasis rubra pilaris","volume":"38","author":"Albert","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jdv.14761","article-title":"Pityriasis rubra pilaris: Algorithms for diagnosis and treatment","volume":"32","author":"Roenneberg","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaad.2018.03.036","article-title":"Biologics for pityriasis rubra pilaris treatment: A review of the literature","volume":"79","author":"Napolitano","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","article-title":"Pityriasis rubra pilaris","volume":"5","author":"Griffiths","year":"1980","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40257-023-00836-x","article-title":"Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options","volume":"25","author":"Joshi","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ricci, A.A., Dapavo, P., Mastorino, L., Roccuzzo, G., Wolff, S., Ribero, S., Cassoni, P., Senetta, R., and Quaglino, P. (2023). Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216820"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(89)70093-1","article-title":"Pityriasis rubra pilaris: A review of diagnosis and treatment","volume":"20","author":"Cohen","year":"1989","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaad.2018.02.034","article-title":"CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris","volume":"79","author":"Craiglow","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., and Fang, H. (2020). The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.594735"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/CCID.S407812","article-title":"Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?","volume":"16","author":"Megna","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/archderm.1969.01610240068012","article-title":"Pityriasis rubra pilaris. Report of a case and analysis of the literature","volume":"99","author":"Gross","year":"1969","journal-title":"Arch. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2230.1988.tb00716.x","article-title":"Pityriasis rubra pilaris and vitiligo in Down\u2019s syndrome","volume":"13","author":"Hazini","year":"1988","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_14","first-page":"626","article-title":"Pityriasis rubra pilaris and celiac sprue with malabsorption","volume":"25","author":"Randle","year":"1980","journal-title":"Cutis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/archderm.1965.01600160080018","article-title":"Vitamin A responsive pityriasis rubra pilaris with myasthenia gravis","volume":"92","author":"Waldorf","year":"1965","journal-title":"Arch. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1468-3083.2007.02502.x","article-title":"A case of pityriasis rubra pilaris associated with sacroileitis and autoimmune thyroiditis","volume":"22","author":"Soylu","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.1995.tb06939.x","article-title":"Pityriasis rubra pilaris and human immunodeficiency virus infection","volume":"133","author":"Miralles","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_18","first-page":"818","article-title":"Pityriasis rubra pilaris and HIV infection: A part of the spectrum of HIV-associated follicular syndrome","volume":"133","author":"Fuentes","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_19","first-page":"e43810","article-title":"A Rare Post-infectious Rash: Pityriasis Rubra Pilaris After COVID-19 Infection","volume":"15","author":"Duncan","year":"2023","journal-title":"Cureus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3760\/cma.j.issn.0366-6999.20133239","article-title":"Pityriasis rubra pilaris (PRP) with preceding Epstein-Barr virus infection: A new type PRP with non-HIV virus infection?","volume":"127","author":"Wang","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1111\/j.1365-2230.2009.03678.x","article-title":"A case of juvenile pityriasis rubra pilaris: Could varicella be an aetiological agent?","volume":"34","author":"Ertam","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_22","first-page":"1421","article-title":"Pityriasis rubra pilaris in association with hepatitis A","volume":"27","author":"Erdem","year":"2006","journal-title":"Saudi Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ced.12081","article-title":"Pityriasis rubra pilaris-like reaction induced by imatinib","volume":"38","author":"Plana","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_24","first-page":"1161","article-title":"Sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption","volume":"14","author":"Cheung","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/ijd.15563","article-title":"Pityriasis rubra pilaris induced by PD-1 inhibitor nivolumab","volume":"60","author":"Goldberger","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e14085","DOI":"10.1111\/dth.14085","article-title":"Nilotinib-induced pityriasis rubra pilaris: Frst case report","volume":"33","author":"Lahouel","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.abd.2022.04.016","article-title":"Pityriasis rubra pilaris induced by topical use of imiquimod 5","volume":"98","author":"Altemir","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.annder.2011.01.049","article-title":"Pityriasis rubra pilaire apr\u00e8s vaccination [Pityriasis rubra pilaris after vaccination]","volume":"138","author":"Waton","year":"2011","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ced.14878","article-title":"Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine","volume":"47","author":"Hunjan","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/DAD.0000000000002369","article-title":"Pityriasis Rubra Pilaris After Moderna COVID-19 Vaccination: A Case Report and Literature Review","volume":"45","author":"Liu","year":"2023","journal-title":"Am. J. Dermatopathol."},{"key":"ref_31","first-page":"e833","article-title":"Pityriasis rubra pilaris after Vaxzevria\u00ae COVID-19 vaccine","volume":"35","author":"Fraga","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1111\/jdv.18341","article-title":"Reply to \u2018Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study\u2019 by Bawane J et\u2009al","volume":"36","author":"Potestio","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/jdv.18531","article-title":"Skin reaction after SARS-CoV-2 vaccines Reply to \u2018cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: A real-life multicentre experience\u2019","volume":"37","author":"Martora","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ced\/llac012","article-title":"Comment on \u2018Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine\u2019","volume":"48","author":"Potestio","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_35","first-page":"610","article-title":"Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma","volume":"13","author":"Remedios","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2230.2005.01781.x","article-title":"Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma?","volume":"30","author":"Batchelor","year":"2005","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_37","first-page":"100","article-title":"Pityriasis rubra pilaris as the initial manifestation of leukemia","volume":"31","author":"Reinhardt","year":"1983","journal-title":"Cutis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2010.05.013","article-title":"Pityriasis rubra pilaris: Was it the first manifestation of colon cancer in a patient with pre-existing psoriasis?","volume":"68","author":"Vitiello","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000246088","article-title":"Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma","volume":"194","author":"Sharma","year":"1997","journal-title":"Dermatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5070\/D365618361","article-title":"Pityriasis rubra pilaris","volume":"9","author":"White","year":"2003","journal-title":"Dermatol. Online J."},{"key":"ref_41","first-page":"243","article-title":"Systemic therapies of pityriasis rubra pilaris: A systematic review","volume":"17","author":"Kromer","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2012.10.043","article-title":"Confocal reflectance microscopy in pityriasis rubra pilaris","volume":"68","author":"Pietroleonardo","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2147\/CCID.S124351","article-title":"Management of refractory pityriasis rubra pilaris: Challenges and solutions","volume":"10","author":"Moretta","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11530070-000000000-00000","article-title":"Pityriasis Rubra Pilaris","volume":"11","author":"Klein","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1525-1470.2007.00603.x","article-title":"Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment","volume":"25","author":"Parissa","year":"2008","journal-title":"Pediatr. Dermatol."},{"key":"ref_46","first-page":"340","article-title":"Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%","volume":"6","author":"Gregoriou","year":"2007","journal-title":"J. Drugs Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2230.2000.00616.x","article-title":"Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving RE-PUVA therapy","volume":"25","author":"Neess","year":"2000","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients","volume":"152","author":"Ross","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000327704","article-title":"Oral alitretinoin for the treatment of recalcitrant pityriasis rubra pilaris","volume":"3","author":"Schmitt","year":"2011","journal-title":"Case Rep. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.jaad.2013.01.036","article-title":"Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin","volume":"69","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/dth.12320","article-title":"Circumscribed juvenile pityriasis rubra pilaris responsive to alitretinoin","volume":"29","author":"Yun","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5021\/ad.2016.28.3.388","article-title":"Classic Juvenile Pityriasis Rubra Pilaris Treated with Oral Alitretinoin","volume":"28","author":"Lee","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0190-9622(90)70110-4","article-title":"Pityriasis rubra pilaris: Further observations of systemic retinoid therapy","volume":"22","author":"Borok","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2340\/00015555-2885","article-title":"Methotrexate Treatment for Pityriasis Rubra Pilaris: A Case Series and Literature Review","volume":"98","author":"Koch","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1468-3083.2007.02282.x","article-title":"Type III juvenile pityriasis rubra pilaris: A successful treatment with infliximab","volume":"22","author":"Ruzzetti","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_56","first-page":"1071","article-title":"Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate","volume":"7","author":"Barth","year":"2009","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/12034754231223159","article-title":"Updates on Pityriasis Rubra Pilaris: A Scoping Review","volume":"28","author":"Zhou","year":"2024","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2008.05.037","article-title":"Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy","volume":"59","author":"Gattringer","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1111\/j.1468-3083.2012.04456.x","article-title":"A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists","volume":"27","author":"Petrof","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamadermatol.2013.4773","article-title":"Treatment options for pityriasis rubra pilaris including biologic agents: A retrospective analysis from an academic medical center","volume":"150","author":"Eastham","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e12443","DOI":"10.1111\/dth.12443","article-title":"Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu\u2019s arteritis","volume":"30","author":"Salman","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamadermatol.2015.3405","article-title":"Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast","volume":"152","author":"Krase","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/dth.13060","article-title":"Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_64","first-page":"e41125","article-title":"The Effectiveness of Anti-Interleukin-17A Treatment for Pityriasis Rubra Pilaris: A Systematic Review","volume":"15","author":"Abduljawad","year":"2023","journal-title":"Cureus"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/12034754241238735","article-title":"Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review","volume":"28","author":"Chandy","year":"2024","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_67","first-page":"102","article-title":"Bimekizumab in refractory pityriasis rubra pilaris","volume":"22","author":"Kromer","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.21708","article-title":"Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: A single-arm clinical trial with transcriptomic analysis","volume":"187","author":"Boudreaux","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e14097","DOI":"10.1111\/dth.14097","article-title":"Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review","volume":"33","author":"Liang","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdcr.2022.07.015","article-title":"Pityriasis rubra pilaris rapidly cleared with ixekizumab in an HIV-positive patient","volume":"27","author":"Kranyak","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1002\/ski2.139","article-title":"Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination","volume":"3","author":"Liu","year":"2022","journal-title":"Skin Health Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jdcr.2023.03.003","article-title":"Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab","volume":"35","author":"Zhao","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/ijd.14857","article-title":"Familial pityriasis rubra pilaris successfully treated with brodalumab","volume":"59","author":"Graceffa","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_75","first-page":"e112","article-title":"Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab","volume":"60","author":"Tubau","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_76","first-page":"e249","article-title":"Successful treatment of Pityriasis rubra pilaris with brodalumab","volume":"61","author":"Gambardella","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2023.09.024","article-title":"Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab","volume":"42","author":"Saad","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamadermatol.2024.0257","article-title":"Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23\/IL-17 and NFkB Signaling: A Nonrandomized Trial","volume":"160","author":"Velasco","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamadermatol.2019.2774","article-title":"Treatment of Pityriasis Rubra Pilaris With Guselkumab","volume":"155","author":"Pilz","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e6413","DOI":"10.1002\/ccr3.6413","article-title":"Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris","volume":"10","author":"Nishimura","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e14403","DOI":"10.1111\/dth.14403","article-title":"Successful treatment of pityriasis rubra pilaris with guselkumab: Serum CCL20 as a potential marker for the disease activity","volume":"33","author":"Nagai","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00403-021-02262-7","article-title":"Alternative uses of ustekinumab for non-indicated dermatological conditions: A systematic review","volume":"314","author":"Rawal","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.abd.2023.07.009","article-title":"Pityriasis rubra pilaris after COVID-19 vaccination: Successful treatment with ustekinumab","volume":"99","author":"Amoedo","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_84","first-page":"5","article-title":"Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris","volume":"7","author":"Galluzzo","year":"2013","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1111\/bjd.19681","article-title":"Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab","volume":"184","author":"Ricar","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jdcr.2024.03.023","article-title":"Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma","volume":"48","author":"Koroneos","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Holmes, Z., Goh, M.S., Foley, P., and Daniel, B.S. Tildrakizumab use for recalcitrant pityriasis rubra pilaris. Australas. J. Dermatol., 2024.","DOI":"10.1111\/ajd.14307"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/ced\/llad352","article-title":"Rapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab","volume":"49","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ajd.13753","article-title":"Successful treatment of pityriasis rubra pilaris with tildrakizumab","volume":"63","author":"Zagarella","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/ced.14790","article-title":"Refractory Type I pityriasis rubra pilaris treated with tildrakizumab","volume":"46","author":"Licata","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_91","first-page":"e13644","article-title":"Successful treatment of resistant pityriasis rubra pilaris with ixekizumab","volume":"33","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00105-020-04575-6","article-title":"Pityriasis rubra pilaris: Eine erfolgreiche Therapie mit Ixekizumab [Pityriasis rubra pilaris: Successful treatment with ixekizumab]","volume":"71","author":"Kohn","year":"2020","journal-title":"Hautarzt"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14740338.2023.2218086","article-title":"Bimekizumab treatment in patients with moderate to severe plaque psoriasis: A drug safety evaluation","volume":"22","author":"Ruggiero","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, G., and Campanati, A. (2023). Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: A real-life multicenter study-IL PSO (Italian landscape psoriasis). Front. Med., 10.","DOI":"10.3389\/fmed.2023.1243843"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jocd.15543","article-title":"A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab","volume":"22","author":"Megna","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Megna, M., Ruggiero, A., Battista, T., Marano, L., Cacciapuoti, S., and Potestio, L. (2023). Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093233"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s13555-023-01005-y","article-title":"Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children","volume":"13","author":"Kaznowska","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14740338.2022.2160447","article-title":"Drug safety evaluation of tildrakizumab for psoriasis: A review of the current knowledge","volume":"21","author":"Ruggiero","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2017.05.036","article-title":"Early clinical manifestations of S\u00e9zary syndrome: A multicenter retrospective cohort study","volume":"77","author":"Mangold","year":"2017","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/8\/923\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:22:21Z","timestamp":1760109741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/8\/923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":100,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["life14080923"],"URL":"https:\/\/doi.org\/10.3390\/life14080923","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}